Why Omnicell (OMCL) Could Be the Market's Next Healthcare Surprise

Except when it’s tied to a strong narrative and demonstrably explosive growth (think the weight-loss boom), healthcare is usually just a … boring sector. That’s not a bad thing. It would be more fair to say defensive and structurally slow-moving. Those same factors make it appealing in certain environments. But still, certainly not where you’d usually look for bombastic growth.

A note from our sponsors...

The key word there is usually. Every once in a while, a good opportunity arises, but it is admittedly quite rare. Rarer still is when an opportunity like that passes under the radar.

That brings us to today’s stock pick — Omnicell (NASDAQ: OMCL). They’re a small-cap teetering on becoming a mid-cap, with the market cap currently at $1.98 billion. The business provides hospital automation and software that helps manage everything from pharmacy inventory to dispensing and administration at the bedside.

There are over 115 reasons to love this stock … Let’s dig in. 

First, we’ll deal with the fundamentals, and then move on to recent catalysts and the like. Our proprietary quant system, Zen Ratings, evaluates 4,600 stocks each day by comparing them on the basis of 115 fundamental factors. Only the stocks that rank in the top 5% for overall fundamentals are given a Zen Rating of A, and those stocks have provided an average annual return of 32.52% since the early 2000s.

Right now, OMCL ranks in the top 2% of the stocks that we track — so it clears even those high hurdles with ease. OMCL is also the top-rated stock in its industry, Health Information Service, which consists of 45 stocks.

To get a better idea as to what makes Omnicell special, we need to take a look at the 7 Component Grade ratings that make up each stock’s Zen Rating.

As you can see, the fundamental strength here is broad. Good reads on Safety and Value, and exceptional when it comes to Growth and Sentiment. Momentum, Financials, and Artificial Intelligence read as average, but we’ll get into more depth on that later. First, the good stuff.

In terms of the Value Component Grade rating, Omnicell is in the 81st percentile, so equivalent to or better than 81% of stocks. In other words, in the top 19%. Right now, it’s trading at a forward PE of around 29.5x. That might seem like it’s on the expensive side, but the question is what growth prospects are you getting in return.

And the growth prospects are pretty stellar. OMCL is in the top 2% of all the stocks we track with regard to the Growth Component Grade rating. Earnings are estimated to grow by 76% per year — the expectation for the industry is 26.45%, while the estimate for the market is 33.48%.

I mentioned earlier how healthcare is a relatively boring sector. There is an advantage to that, and it’s predictability. That’s exactly what our Safety rating measures, and here, Omnicell is in the top 8%.

Then, we have Sentiment, which tracks analyst recommendations and smart money accumulation. Top 5% in that category. The average Wall Street price target implies an upside of 28.4%, although the highest estimates go as high as 60.5%.

Now, let’s take a look at those C ratings. Momentum is the only below-average score, in the 45th percentile. The Artificial Intelligence rating lands in the 62nd percentile, while Financials clock in at the top 30%.

That’s it for the fundamentals. Time to look at recent catalysts.

The company’s latest quarterly report came out on April 28. Analysts were expecting to see EPS of $0.33, but OMCL delivered $0.55. Since then, this low-profile ticker has surged by about 15%, so it is getting some traction. It’s still in the red by 3.48% on a year-to-date (YTD) basis, but I wouldn’t be surprised if the rally continues.

There’s one last thing to mention. Healthcare automation, a major part of Omnicell’s business, isn’t a space that goes through incremental upgrades. It has long replacement cycles. A new platform can drive a sustained wave of hospital replacements that plays out over years, not quarters.

That’s where Titan XT comes in. This is Omnicell’s next-generation automated dispensing platform, designed to modernize how hospitals manage medication storage and distribution at scale. While still early in its rollout, management has pointed to growing customer engagement and early adoption interest, particularly as hospital systems begin evaluating refresh cycles for their existing automation infrastructure 

So, all in all: exceptional growth prospects, a fair valuation with regard to those growth prospects, stable, strong execution, and plenty of support from Wall Street and smart money. Add to that a new platform, and there are simply too many positive developments here to ignore.

—> Click here to research OMCL

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.